Thursday, February 25, 2021
Wednesday, February 24, 2021
Investor Ideas #Potcasts 535, #Cannabis News and #Stocks on the Move; (NEO: MGW) (OTCQB: $MGWFF) (TSX: $APHA.TO) (NASDAQ: $APHA) (NASDAQ: $TLRY) (CSE: $AUSA.C)
Investor Ideas #Potcasts 535, #Cannabis News and #Stocks on the Move; (NEO: MGW) (OTCQB: $MGWFF) (TSX: $APHA.TO) (NASDAQ: $APHA) (NASDAQ: $TLRY) (CSE: $AUSA.C)
Delta, Kelowna, BC, February 24, 2021 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
https://www.investorideas.com/Audio/Podcasts/2021/022421-StocksToWatch.mp3
Read this in full at https://www.investorideas.com/news/2021/cannabis-potcasts/02241MGWFF-APHA-TLRY-AUSA.asp
Hear the investor ideas potcast on Spotify
Hear Investor ideas cannabis potcast on iTunes
Today’s podcast overview/transcript:
Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.
In today’s podcast we look at a few public and private company announcements.
Everest BioPharma International Inc. announced that it has received, in February 2021, its notification of Eligible Business corporation ("EBC") under the BC Venture Capital Act allowing BC investors a 30% Tax Credit. The Company is presently completing the internal build-out of its state-of-the art cannabis extraction systems in Kelowna, BC. The first sales of live rosen and its derivatives are expected in May, 2021.
Everest is installing large capacity ice water bubble hash solventless processing equipment with ancillary rosen presses, which also allows the ability for "organic" registration, adding further value to its products.
Nigel Boast, President and CEO of Everest BioPharma stated; "Our registration as an eligible business corporation "EBC" in BC (attracting a 30% tax credit) will facilitate funding required for us to fully implement our business plan which firstly focuses on tolling service fees and then the sale of our proprietary medical CBD products. Two recent standard processing license sales: Premium 5 with a similar business model ($40M), and LYF Food ($43M) indicate a high valuation for Everest.
Rob Hatch, COO of Everest BioPharma stated; "By processing from frozen, we save our tolling customers time and money because there is no requirement to trim and dry the product. There are approximately 147 standard cultivation licenses in Canada without extraction licenses."
Aphria Inc. (TSX: APHA) (NASDAQ: APHA), a leading global cannabis-lifestyle consumer packaged goods company inspiring and empowering the worldwide community to live their very best life, and Tilray, Inc. (NASDAQ: TLRY), a global pioneer in cannabis research, cultivation, production and distribution, announced the launch of the website: www.aphriatilraytogether.com. This new, dedicated resource seeks to provide shareholders of both companies with pertinent information, news and updates leading up to the special meetings of shareholders at which Aphria's and Tilray's respective shareholders will vote on the resolutions necessary to implement the proposed business combination of the two companies. The website will also allow shareholders and other interested parties to register for Transaction updates that are made publicly available, so they receive information directly to their e-mail addresses.
As disclosed in the preliminary joint proxy statement and management information circular filed with regulators on February 19, 2021, both companies are pleased that the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, has expired in relation to the Transaction. In addition, the companies have received a no-action letter from the Competition Bureau of Canada in respect of the Transaction, which confirms that the Competition Bureau does not intend to challenge the Transaction under the Competition Act (Canada). The receipt of the HSR Clearance and the Competition Act Approval are two of the required regulatory clearances that need to be obtained to satisfy the conditions to closing of the Transaction. The closing of the Transaction is currently expected to occur in the second quarter of calendar year 2021.
Irwin D. Simon, Aphria's Chairman and Chief Executive Officer commented, "The receipt of HSR Clearance and Competition Act Approval represent a significant step forward in bringing together these two companies, and we are incredibly pleased that we remain on track to complete our business combination in the second quarter of calendar year 2021. Together, Aphria and Tilray expect to have a robust strategic footprint in Canada and internationally with the operational scale necessary to compete more effectively in today's consolidating cannabis market. We believe our strong, flexible balance sheet, cash position and access to capital will provide us with the ability to accelerate long-term sustainable growth and deliver attractive returns for shareholders."
Australis Capital Inc. (CSE: AUSA) (OTC: AUSAF) announced today that, further to its press release dated January 5, 2021, the Company has entered into a definitive agreement with the principals of ALPS for the acquisition of 51% of the issued and outstanding shares in ALPS. The Definitive Agreement has an option permitting the Company to acquire the remaining 49%. Furthermore, the ALPS Transaction also includes the appointment of Terry Booth as AUSA's CEO upon completion.
Since its management buyout from Aurora Cannabis in May 2020, ALPS has rapidly built a blue-chip roster of global customers and a growing pipeline of potential new deals. ALPS currently is executing on a number of contracts, including four that were signed and announced in the past month:
● Aurora Cannabis - Annual ongoing services contract, multiple locations globally
● Cann Group - Cannabis facility contract + APIS extended services contract in Australia
● Multiple undisclosed cannabis related contracts in the U.S.
● Bluehouse Greenhouse – 62 acre vegetable facility contract in California, U.S.
● Vertical Harvest – 200,000 sqft multi-level urban facility contract in Wyoming, U.S.
● Aldershot Greenhouses – 200,000 sqft facility expansion contract in Ontario, Canada
● 200,000 sqft small plant production facility in Finland
● 20,000 sqft crop research facility in northern U.S.
● Tropica – facility for the cultivation of aquarium plants in Germany
● McMaster University, life Science Centre, Ontario, Canada
● Queen, Denmark – ornamental plants
● Middle East – large fruit & vegetable facility
The ALPS Transaction, upon closing, will be immediately accretive to AUSA results, with further material growth anticipated in the coming months.
Maple Leaf Green World Inc. (NEO: MGW) (OTCQB: MGWFF) announced that it has signed an agreement with Hempacco Co. Inc., a vertically integrated California-based Hemp CBD, CBG R&D, marketing, and manufacturing company, to develop, manufacture and market its new brand of CBG Hemp cigarettes.
The Agreement aims to develop a new CBG hemp cigarette brand for Maple Leaf using their California-grown hemp. Hempacco will handle all of the research, development, and manufacturing of a retail-ready 20-pack CBG-rich hemp cigarette brand.
"I’m excited to work with Hempacco to develop our brand of CBG hemp cigarettes; this is a pivot for our company after identifying the growing hemp cigarette space and the market opportunity not only in the USA, but also in Canada and internationally”, said Raymond Lai, CEO of Maple Leaf, “Our CBG farm is minutes away from Hempacco’s manufacturing location, which makes it an amazing opportunity to have our own seed to shelve product and deliver an incredible hemp smokable quality experience to the consumer,” Raymond concluded.
“It’s been a pleasure working with Raymond and his team to launch Maple Leaf’s new CBG brand in our quest to disrupt Tobacco™,” said Sandro Piancone, CEO of Hempacco. “We’re committed to a fast launch of the CBG hemp cigarette brand and following it up with an eCommerce portal that integrates picking, packing, and shipping all from one location close to the Maple Leaf’s farm,” Sandro concluded.
The hemp cigarette private label manufacturing agreement is for five (5) years consists of two (2) phases. The first phase is hemp cigarette product development, including Research & Development, Business Modelling, and hemp cigarette white label Manufacturing sub-phases. Hempacco will undertake all the necessary work for the three (3) sub-phases, including packaging and shipping, where Maple Leaf supplies raw hemp material. Maple Leaf and Hempacco will jointly develop branding and packaging artwork that Hempacco will manufacture. The second phase is to establish an e-commerce Strategy, which will expand Maple Leaf’s online and social media presence by developing a full e-commerce platform. Through the Company’s new hemp cigarette online store, CBG hemp cigarettes, packaged flower jars, and subsequent product developments will be available for purchase and shipped across the United States and Overseas. Both phases will commence immediately.
Hempacco will invest in the brand by paying for all the initial start-up costs associated with both phases. Maple Leaf will contribute to the manufacturing and order processing cost when sales are made. As compensation for Hempacco’s services, Maple Leaf will pay Hempacco two (2) million common shares at $0.075 per share for phase 1 and one (1) million common shares at $0.075 per share for phase 2 provided that both phases are completed within 45 days after the agreement date and accepted by Maple Leaf. The issuance of three (3) million common shares is subject to Maple Leaf’s Broad of Directors and Neo Stock Exchange's approval.
The Agreement will leverage Hempacco’s fully integrated supply chain to manufacture, package, market, and distribute Maple Leaf’s CBG Hemp Cigarettes as well as leveraging Maple Leaf’s digital branding artwork, expertise in cultivating high quality, organic CBG Hemp, and its role as a gateway for penetrating international markets. By utilizing the resources from both Maple Leaf and Hempacco, the Agreement will disrupt the cigarette industry by providing a naturally great-tasting alternative to traditional tobacco and nicotine cigarettes. Hemp cigarettes are also a great alternative to marijuana by offering the non-psychoactive effects caused by THC with the added benefits of CBG.
Investors can trade these stocks and other ideas on our site using our list of top stock trading apps including Robinhood , Acorn, Stash and others.
Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and that this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment.
Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
Hear the investor ideas potcast on Spotify
To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
Investorideas.com podcasts are also available on iTunes, Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change , Exploring Mining the AI Eye .
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy:
https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.
Follow us on Twitter https://twitter.com/Investorideas
Follow us on Facebook https://www.facebook.com/Investorideas
Follow us on YouTube https://www.youtube.com/c/Investorideas
Download our Mobile App for iPhone and Android
Join our Investor Club https://www.investorideas.com/membership/
Contact Investorideas.com
800 665 0411
Get more Cannabis Stock Investor Ideas – news, articles, podcasts and stock directory
#Psilocybin Sector Snapshot; #Stocks Discussed (OTC: $LRSV) (OTCQB: $SHRMF) (OTCQB: $MMEDF) (OTC: $RVVTF) @res_pet @mindmedco @Revive_RVV
#Psilocybin Sector Snapshot; #Stocks
Discussed (OTC: $LRSV) (OTCQB: $SHRMF) (OTCQB: $MMEDF) (OTC: $RVVTF) @res_pet
@mindmedco @Revive_RVV
Point
Roberts WA, Delta BC – February 24, 2021 - Investorideas.com, a
leading investor news resource on health and wellness stocks releases a sector
snapshot looking at a health revolution taking place with the growing
functional mushroom and psychedelic mushroom markets, featuring Link Reservations Inc. (OTC PINK: LRSV).
Read this news,
featuring LRSV in full at https://www.investorideas.com/news/2021/lohas/02241Psilocybin-Stocks.asp
According
to Data Bridge Market
Research, “The functional mushroom market is expected to gain
market growth in the forecast period of 2021 to 2028. Data Bridge Market
Research analyses that the market is growing with the CAGR of 7.22% in the
forecast period of 2021 to 2028 and is expected to reach USD 555.94 billion by
2028. The increasing use of the ingredient in the healthcare sector is
escalating the growth of functional mushroom market.”
New to the functional mushroom market, Link
Reservations Inc. (OTC PINK: LRSV), a provider of wellness and cannabidiol
(CBD) products for both humans and pets just announced the expansion
of its DailyLifeCBD product line to include a suite of functional
mushroom-infused products. The Company, having recently acquired DailyLifeCBD to enter the
health and wellness sector, is looking to expand its range of complementary
well-being products with an emphasis on natural and organic ingredients.
Due to the Covid-19 global pandemic, consumers are
increasingly searching for ways to boost their immune system, seen by the
market growth of alternative and complementary products. Functional (or
medicinal) mushrooms possess beneficial properties such as antibacterial,
anti-inflammatory and immunomodulating effects - meaning they help keep the
immune system in balance. Functional mushrooms are specific varieties, such as
Shiitake, Reishi, Maitake and Chaga, amongst others.
Having recently expanded into the health and
wellness sector through its acquisition of DailyLifeCBD - a website
selling CBD products for people - LRSV is now pursuing the development and
commercialization of rapid onset treatments capable of improving health
outcomes such as depression and post-traumatic stress disorder (PTSD), as well
as substance and alcohol use disorders.
"We are very excited and much looking forward
to the opportunity for growth brought by the sale and distribution of our new
premium, functional mushroom-infused suite of products. As a Company, our focus
continues to be on providing high quality, natural products that can benefit
the health and wellbeing of consumers," commented Rene Lauritsen, CEO at Link
Reservations Inc. "At the same time we aim to continue growing our revenue
and increasing shareholder value through acquisitions and product range
expansion. The LRSV team is confident of the potential that this new product
suite has in enhancing the health and wellness of millions of consumers,"
he added.
The Company plans to initiate activities through
DailyLifeCBD with a range of non-edible lifestyle products for people and
expand on the range as the site and demand grows. LRSV is considering the possibility
of a subsidiary solely focused on its mushroom-infused products.
"Our expectation, based on discussions with
our manufacturer is to have these new products available for sale in the coming
weeks - we are very excited by this. We will keep shareholders and the
investment community updated through press releases as developments
arise," said Lauritsen.
Finally, if and when Federal and jurisdiction laws
allow, Link Reservations Inc. (OTC PINK: LRSV) is setting its eyes on a greater prize, with a
potential suite of psychedelic mushroom-infused products to follow the
functional mushroom products.
The
Psychedelic mushroom stock sector has grown enough that an ETF has been created
around it, currently trading on the NEO Exchange, the HORIZONS PSYCHEDELIC STOCK INDEX ETF is an
indication of future growth opportunities.
TOP
10 HOLDINGS AS AT FEBRUARY 12, 2021:
Security Name Weight
SEELOS THERAPEUTICS
INC 12.51%
NUMINUS WELLNESS
INC 10.09%
FIELD TRIP HEALTH
LTD 9.99%
MIND MEDICINE
(MINDMED) INC SUB VTG 9.49%
COMPASS PATHWAYS
PLC ADR 8.71%
RED LIGHT HOLLAND
CORP 6.9%
GREENBROOK TMS INC
NEW 6.82%
CYBIN INC 6.24%
REVIVE THERAPEUTICS
LTD. 5.14%
JOHNSON &
JOHNSON 4%
Last week, Revive Therapeutics Ltd.
(CSE: RVV) ( RVVTF), a
specialty life sciences company focused on the research and development of
therapeutics for medical needs and rare disorders and one of the holdings in
the ETF announced that,
further to its press release dated December 21, 2020, it has entered into an
asset purchase agreement with Newscope Capital Corporation (CSE: PHRM) (OTCQB:
PHRRF) to acquire the full rights to PharmaTher Inc.’s intellectual property (the “Acquired Assets”)
pertaining to psilocybin (the “Acquisition”). PharmaTher, a wholly-owned
subsidiary of Newscope, is a specialty life sciences company focused on the
research and development of psychedelic pharmaceuticals.
“With this acquisition, we have
solidified our foundation in having a leading psychedelics pharmaceutical
platform with a focus on proprietary psilocybin-based therapeutics that
includes the development of an oral thin film product in collaboration with the
University of Wisconsin-Madison, a novel biosynthetic version of psilocybin
based on a natural biosynthesis enzymatic platform developed by Dr. Gavin
Williams, Professor and Researcher at North Carolina State University, a
clinical study with the University of Wisconsin evaluating psilocybin in the
treatment of methamphetamine use disorder, and PharmaTher’s psilocybin research
initiatives and intellectual property in stroke, traumatic brain injury, cancer
and drug combinations,” said Michael Frank, CEO of Revive. “We are now in a
position to advance our psilocybin program for future clinical development in
various unmet clinical needs in mental health, cancer and neurological
disorders.”
Looking at how psychedelic mushrooms
may be playing a role in mental health, in late January Champignon Brands Inc.
(OTCQB: SHRMF)
Chairman and CEO, Roger McIntyre announced the
opening of a new Canadian Rapid Treatment Center of Excellence (CRTCE) clinic
in Ottawa, Ontario. This third clinic joins the Mississauga and Toronto clinics
(CRTCE Clinics) in addressing the unmet need of depression and suicide through
novel ketamine therapy treatment.
“Over twenty clinical trials have
demonstrated that ketamine and esketamine have rapid and robust antidepressant
effects in patients that have failed to respond to conventional
antidepressants. During the COVID-19 pandemic, the need for effective treatment
has become exponentially critical," said Dr. Joshua Rosenblat, Medical
Director, CRTCE. "Ketamine treatment for depression is very difficult to
access in Canada. This third clinic should allow more people to access treatment."
MindMed (NEO:MMED) (OTCQB:MMEDF), a
psychedelic medicine biotech company that discovers, develops and deploys
psychedelic inspired medicines and therapies to address addiction and mental illness
announced just
recently that it will acquire HealthMode, a digital medicine and
therapeutics startup that uses Artificial Intelligence (AI)-enabled digital
measurement to increase the precision and speed of clinical research and
patient monitoring.
MindMed Co-Founder and CEO, J.R.
Rahn said, "Our mission is to make MindMed as much a digital medicine
company as a drug development company. With the addition of Dan and Bradford's
team of engineers and product experts, our digital medicine division, Albert,
is now the Special Ops of digital medicine, applying machine learning to drug
development and patient care. The future of modern mental healthcare and
psychedelic medicine ultimately will rely on improving infrequent,
self-reported and observed measures for mental health to a paradigm where the
continual digital measurement of our mind and body is as vital as the drug
treatment itself. In effect, we see a future mental health treatment paradigm
where potential drug products such as our LSD experiential therapy might be
prescribed right alongside software application programming interfaces (APIs)
to prepare the patient for treatment and optimally monitor the after-care of
one's anxiety disorder."
What does the future hold for
functional and psychedelic mushrooms for consumers and investors? According to a recent article,”After
successfully traveling through the niche wellness-to-mainstream pipeline,
mushrooms are set to get more “magical” with the prospect of wider legalization
of psychedelics.”
Investors can research the sector
with a list of health and wellness
stocks at
Investorideas.com
Investors can research psychedelic
stocks at https://www.investorideas.com/Marijuana-Stocks/Stocks_List.asp
About
Investorideas.com - News that Inspires Big Investing Ideas Investorideas.com is a recognized news source publishing third
party news, research and original financial content. Learn about investing in
stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining,
sports biotech, water, renewable energy and more. Investor Idea’s original
branded content includes the following podcasts and columns : Crypto Corner , Play
by Play sports and stock news column, Investor Ideas
Potcasts Cannabis News and Stocks on the Move
podcast and column, Cleantech
and Climate Change , Exploring
Mining
the AI
Eye .
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles
and equity research as well as creates original content, including video,
interviews and articles. Original content created by investorideas is protected
by copyright laws other than syndication rights. Our site does not make
recommendations for purchases or sale of stocks, services or products. Nothing
on our sites should be construed as an offer or solicitation to buy or sell
products or securities. All investing involves risk and possible losses. This
site is currently compensated for news publication and distribution, social
media and marketing, content creation and more. Disclosure is posted for each
compensated news release, content published /created if required but otherwise
the news was not compensated for and was published for the sole interest of our
readers and followers. Contact management and IR of each company directly
regarding specific questions. Disclosure: this news article featuring
LRSV is a paid for news release on Investorideas.com – third party: Learn more about
the cost of publishing your news release and our article creation https://www.investorideas.com/News-Upload/ and
tickertagstocknews.com
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other
news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and
tickertagstocknews.com
Global investors must adhere to regulations of each country.
Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Contact
Investorideas.com
800-665-0411
Subscribe to:
Posts (Atom)